The purpose of the Administration Core is to support the translational research objectives of our SPORE in Thyroid Cancer by serving as the organizational hub, optimizing collaboration annong SPORE investigators within and outside MSKCC.
The specific aims ofthe Administrative Core are 1) Provide coordination for all educational and scientific activities ofthe SPORE and 2) Provide centralized administrative support of day- to-day activities to all the components of the SPORE: research projects, cores, and developmental programs. The core will perform the following centralized duties: ? Scientific Review Coordination: Organize the scientific review of ongoing SPORE research projects, cores, and pilot projects as well as the annual solicitation of new pilot projects ? Collaboration: Foster collaborative research within our SPORE as well as with other SPOREs and the wider scientific community ? Financial Management: Serve as the centralized SPORE budgetary coordinator and financial manager ? Editorial Services: Provide editorial services for manuscript publication and grants coordination ? Grants Administration: Serve as administrative liaison to the National Cancer Institute, ensuring the timely submission of all required reports and compliance with institutional and federal regulations. The Administrative Core is led by James Fagin, MD, the SPORE Project Director/Principal Investigator, who will oversee all SPORE activities. Steven Larson, MD will serve as the Co-Director on the core and assist Dr. Fagin. The Administrative Core also includes Jeffrey Knauf, PhD, who will coordinate collaborations, educational functions and meetings, and Mr Matthew Skernolis, who will serve as the financial manager, administrator ofthe grant and coordinate communications with the National Cancer Institute and compliance with institutional and federal regulations.
The Administrative Core serves the essential purpose of centralizing and optimizing collaboration between SPORE investigators. In addition it will provide the institutional environment for proper monitoring of scientific progress, administrative compliance and financial management.
|Ibrahimpasic, Tihana; Xu, Bin; Landa, Iñigo et al. (2017) Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clin Cancer Res 23:5970-5980|
|Orlacchio, Arturo; Ranieri, Michela; Brave, Martina et al. (2017) SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance. Cancer Res 77:6914-6926|
|Montero-Conde, Cristina; Leandro-Garcia, Luis J; Chen, Xu et al. (2017) Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene. Proc Natl Acad Sci U S A 114:E4951-E4960|
|Park, Spencer; Shevlin, Enda; Vedvyas, Yogindra et al. (2017) Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep 7:14366|
|Min, Irene M; Shevlin, Enda; Vedvyas, Yogindra et al. (2017) CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors. Clin Cancer Res 23:7569-7583|
|Sherman, Eric J; Dunn, Lara A; Ho, Alan L et al. (2017) Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer 123:4114-4121|
|Di Cristofano, Antonio (2017) SGK1: The Dark Side of PI3K Signaling. Curr Top Dev Biol 123:49-71|
|Anelli, Viviana; Villefranc, Jacques A; Chhangawala, Sagar et al. (2017) Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression. Elife 6:|
|Brito, Juan P; Ito, Yasuhiro; Miyauchi, Akira et al. (2016) A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. Thyroid 26:144-9|
|Mandal, Rajarsi; Chan, Timothy A (2016) Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov 6:703-13|
Showing the most recent 10 out of 29 publications